Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2011

Janjigian Yelena Y, Park Bernard J, Zakowski Maureen F, Ladanyi Marc, Pao William, D'Angelo Sandra P, Kris Mark G, Shen Ronglai, Zheng Junting, Azzoli Christopher G

Abstract excerpt

BACKGROUND: Patients with stage IV lung adenocarcinoma and epidermal growth factor receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs). Whether treatment with TKI improves outcomes in patients with resected lung adenocarcinoma and EGFR mutation is unknown. METHODS: Data were analyzed from a surgical database of patients with resected lung adenocarcinoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to DNA, Neoplasm

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Quinazolines

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 21150674
DOI: 10.1097/JTO.0b013e318202bffe
PMCID: PMC3778680

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.PMID 21150674Read ↗

Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma.Semantic proximity Read ↗

Prognostic implication of EGFR mutation status and subtype in resected lung adenocarcinoma patients irrespective of therapy.Semantic proximity Read ↗

Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas.Semantic proximity Read ↗

Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.Semantic proximity Read ↗

Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.Semantic proximity Read ↗

Prognostic implications of combining EGFR-TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19-Del or 21-L858R mutations: A real-world study.Semantic proximity Read ↗

Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.Semantic proximity Read ↗

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.Semantic proximity Read ↗

Prognostic Impact of EGFR Driver Mutations on Postoperative Disease Recurrence in Lung Adenocarcinoma.Semantic proximity Read ↗

[Clinical characteristics and outcomes of lung cancer patients with EGFR mutations in exons 19 and 21].Semantic proximity Read ↗

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.Semantic proximity Read ↗

Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.